drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Allogeneic, off-the-shelf induced pluripotent stem cell–derived natural killer cells engineered with a chimeric antigen receptor targeting CD33 (Siglec-3) on AML blasts to redirect NK recognition and trigger cytotoxic killing via perforin/granzyme and death-receptor pathways while sparing normal hematopoietic stem cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Natural Killer Cells
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic iPSC-derived natural killer cells engineered with an anti-CD33 chimeric antigen receptor bind CD33 on AML blasts, redirecting NK activation to induce cytotoxic killing via degranulation (perforin/granzyme) and death-receptor pathways (e.g., FasL/TRAIL), with intent to spare normal hematopoietic stem cells with low/absent CD33 expression.
drug_name
iPSC-derived CAR-NK cells (anti-CD33)
nct_id_drug_ref
NCT06367673